ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 395

Depression Risk Among Adults with Childhood- and Adult-Onset Systemic Lupus Erythematosus: 11 Years of Follow-up

Erica F. Lawson1, Andrea Knight2, Laura Trupin3, Patricia P. Katz3 and Edward H. Yelin4, 1Pediatrics/Rheumatology, UC San Francisco, San Francisco, CA, 2Pediatrics/Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 3Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, 4Medicine/Rheumatology, UC San Francisco, San Francisco, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: longitudinal studies, mental health, outcomes and pediatric rheumatology

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Lupus, Scleroderma, JDMS

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Neuropsychiatric syndromes are prevalent in childhood-onset systemic lupus erythematosus (cSLE), but the long-term risk of depression in adults with cSLE is unknown. We compared the prevalence of depression among adults with cSLE to those with adult-onset SLE (aSLE) using the UCSF Lupus Outcomes Study (LOS).

Methods:

Data derive from the 2002-2012 cycles of the LOS, an annual longitudinal telephone survey of diverse English-speaking individuals with confirmed SLE. Participants aged 18-45 years (N=520) were included. Respondents were classified as childhood-onset if age at diagnosis was <18 years (N=112).  Mental health was assessed with the Center for Epidemiological Studies Depression Scale (CESD), the ACR Committee on Neuropsychiatric Lupus’ suggested measure of depression in SLE, using validated cutoff values. Outcome variables included CESD≥24 (indicative of major depression) and CESD≥20 (indicative of a mood disorder). We performed repeated measures analysis using generalized estimating equations to compare cSLE and aSLE with and without adjustment for other characteristics that could affect depression risk. Age, gender, non-white ethnicity, marital status, poverty, education attained, obesity, self-reported disease activity according to the Systemic Lupus Activity Questionnaire (SLAQ) score, and physical disability according to the SF-36 Scale of Physical Function (SF36-PF) were included as covariates.

Results:

Respondents with cSLE were younger at baseline (26±7 v. 35±6), more likely to be male (13% v. 5%), and more likely to be ethnic minorities (60% v. 46%), all p<0.01. Mean age at diagnosis was 14±3 for respondents with cSLE as compared to 27±6 for those with aSLE. Mean disease duration at baseline was 13±7 years in the cSLE group and 8±6 years in the aSLE group. Mean baseline SLAQ score was 12±8 for all respondents. Prevalence of depressed mood at baseline was slightly higher among respondents with aSLE, though not statistically significant (23% vs. 29% for major depression and 31% vs. 35% for all mood disorders). Respondents with aSLE were more likely to have ever taken medication to treat depression (59% vs. 43%, p=0.01). In multivariate analysis, the odds of major depression among participants with cSLE was increased as compared to those with aSLE (OR=1.7, 95% CI 1.1-2.6) after adjustment for covariates (Table 1).

Conclusion:

Onset of SLE in childhood may be an independent risk factor for the development of major depression in early adulthood, with other important predictors including older age, lower educational attainment, increased disease activity and decreased physical function. Appropriate screening and treatment for depression is important to maximize long-term quality of life and functional outcomes in patients with cSLE.

Table 1.  Adjusted and unadjusted odds ratios for the presence of major depression among individuals age 18-45 with SLE*

Variable

Unadjusted OR for major depression (95% CI)

Adjusted OR for major depression (95% CI)†

Childhood-onset SLE

0.8 (0.5-1.1)

1.7 (1.1-2.6)

Age

1.02 (1.00-1.03)

1.04 (1.01-1.06)

Female

1.8 (0.9-3.8)

1.1 (0.5-2.1)

Non-white ethnicity

1.2 (0.9-1.7)

1.2 (0.9-1.7)

Unmarried

1.1 (1.0-1.4)

1.2 (0.9-1.5)

Poverty¶

1.8 (1.4-2.3)

1.1 (0.8-1.6)

Education#

3.3 (2.5-4.2)

2.1 (1.5-2.9)

Obesity%

1.3 (1.0-1.7)

1.0 (0.7-1.3)

Increasing disease activity (SLAQ)

1.14 (1.12-1.16)

1.11 (1.08-1.14)

Decreasing physical function (SF36-PF)

1.06 (1.05-1.07)

1.02 (1.01-1.04)

*OR = odds ratio; 95% CI = 95% confidence interval; SLAQ = Systemic Lupus Activity Questionnaire (0-47); SF36-PF = SF-36 Scale of Physical Functioning (0-100)

† OR adjusted for variables shown

¶ Income below 125% of the Federal poverty level

# Less than a bachelor’s degree attained

% BMI ≥ 30


Disclosure: E. F. Lawson, None; A. Knight, None; L. Trupin, None; P. P. Katz, None; E. H. Yelin, None.

To cite this abstract in AMA style:

Lawson EF, Knight A, Trupin L, Katz PP, Yelin EH. Depression Risk Among Adults with Childhood- and Adult-Onset Systemic Lupus Erythematosus: 11 Years of Follow-up [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/depression-risk-among-adults-with-childhood-and-adult-onset-systemic-lupus-erythematosus-11-years-of-follow-up/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/depression-risk-among-adults-with-childhood-and-adult-onset-systemic-lupus-erythematosus-11-years-of-follow-up/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology